[Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)].

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: A multi-center retrospective study.Chinese medical journal · 2026
   Observational
2. [Chinese expert consensus on the diagnosis and treatment of pulmonary chronic graft-versus-host disease (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
   Article
3. Association between the prognostic nutritional index and early mortality of AML patients after allogeneic HSCT: a retrospective cohort analysis.Frontiers in oncology · 2026
   Article
4. [Impact of donor characteristics on prognosis for myelodysplastic syndromes after haplo-identical transplantation: a retrospective study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
   Article
5. Interleukin Networks in GVHD: Mechanistic Crosstalk, Therapeutic Targeting, and Emerging Paradigms.International journal of molecular sciences · 2025
   Review
6. [Effectiveness and safety of belumosudil in 20 patients with chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
   Article
7. PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantation.Blood cell therapy · 2025
   Article
8. Belumosudil in pediatric patients with chronic graft-versus-host disease after failed multi-line therapy: a case series.Annals of hematology · 2025
   Article
9. ROCK 2 inhibition with belumosudil for the treatment of chronic graft-versus-host disease: a narrative review.Therapeutic advances in hematology · 2025
   Review
10. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy.Leukemia · 2024
    Review
11. [Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Article
12. [Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Article
13. Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research.International journal of medical sciences · 2024
    Article
14. Immune Reconstitution in Pediatric Aplastic Anemia after Allogeneic Hematopoietic Stem-cell Transplantation.International journal of medical sciences · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as